Hologic

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment consists of products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment involves the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Hologic exceeds Q1 earnings, eyes growth in women's health

Hologic's Q1 performance surpassed expectations, driven by strong organic growth and strategic initiatives. The company's commitment to women's health, financial strength, and focus on innovation position it well for future growth. Challenges in Breast Health highlight areas for improvement, while opportunities in new markets and products offer avenues for expansion.

Hologic surpasses Q2 expectations, eyes international growth and women's health

Hologic's Q2 performance exceeded expectations, driven by robust organic revenue growth and strong margins across divisions.
While facing challenges like COVID-related revenue declines and seasonal factors, the company's strategic strengths in women's health and international expansion present growth opportunities.
To sustain growth, Hologic must navigate macro uncertainties, balance growth drivers, and capitalize on opportunities in diagnostics and global expansion.
Overall, Hologic's solid financial results, increased revenue guidance, and strategic initiatives position the company for continued success in the healthcare market.

Hologic excels in Q3 earnings, eyes global growth amid challenges

Hologic delivered strong financial results in Q3 2023, driven by robust revenue growth and strategic product offerings across its divisions.
While facing margin challenges and geopolitical uncertainties, the company remains optimistic about sustaining growth and enhancing profitability through operational improvements.
With a focus on innovation, global expansion, and cautious M&A strategies, Hologic is well-positioned to capitalize on opportunities and navigate challenges in the healthcare market.

Hologic surpasses revenue targets, eyes international growth and strategic M&A

Hologic delivered strong financial performance in Q4 2023, exceeding revenue and EPS targets while emphasizing women's health and innovation.
The company's focus on international growth, strategic capital allocation, and product portfolio strength position it well for continued success.
Challenges in regulatory compliance, M&A decisions, and market dynamics require careful navigation for sustained growth.
Opportunities in international expansion, strategic M&A, and product innovation offer avenues for future growth and market leadership.

Hologic surpasses Q1 revenue expectations, eyes international growth opportunities

Hologic delivered strong Q1 2024 results, exceeding revenue guidance and showcasing robust financial performance with organic growth of 5.2% ex-COVID.
The company's focus on innovation, market expansion, and strong customer relationships positions it well for continued growth and success beyond COVID testing.
While facing challenges such as tough comps in Q2 and potential tax rate impacts, Hologic's disciplined growth strategies and commitment to transformative initiatives offer opportunities for future expansion.
With a strong emphasis on AI capabilities, market expansion, and strategic M&A, Hologic is poised for sustained growth and market leadership in the healthcare sector.

Hologic beats Q2 revenue targets, eyes international growth opportunities

Hologic exceeded revenue and EPS expectations in Q2 2024, showcasing growth in key business segments.
While facing challenges in certain revenue streams, the company is focused on international expansion and margin improvement.
Opportunities lie in leveraging international growth, strategic acquisitions, and product utilization trends.
Overall, Hologic's performance reflects resilience post-COVID and strategic focus on innovation and market positioning.

Hologic surpasses Q3 revenue expectations, eyes international growth opportunities

Hologic's Q3 performance reflects resilience and growth across key business segments, supported by strategic investments and operational excellence. With a focus on innovation and international expansion, the company is well-positioned for sustained growth and value creation in the evolving healthcare landscape.

Hologic exceeds Q4 earnings, eyes international growth and new products

Hologic's Q4 2024 earnings call showcased strong performance, strategic strengths, and growth opportunities. Challenges include maintaining margin expansion and balancing international growth. The company's focus on durable revenue base and new product pipeline sets a positive outlook for fiscal 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women’s health and well-being through early detection and treatment. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The Diagnostics segment offers a range of products, which are used primarily to aid in the screening and diagnosis of human diseases. The GYN Surgical segment is involved in hysteroscopic endometrial ablation systems, tissue removal systems, fluid management systems, and laparoscopic tissue ablation systems and tools. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Graphic Packaging Hld

PulteGroup

PerkinElmer

Top Ranked Growth Stocks to Buy for January 21st

Strength in Molecular Diagnostics business is likely to have continued to aid Hologic's (HOLX) performance in the first quarter of fiscal 2021 amid the coronavirus-led economic doldrums.

Can Diagnostics Aid Hologic (HOLX) Q1 Sales Amid Coronavirus?

SolarEdge Technologies

XPO Logistics

Hologic (HOLX), SolarEdge Technologies (SEDG) and XPO Logistics (XPO) are currently witnessing a short-term pullback in price. So make sure you're taking full advantage of it.

Want More Returns? Invest in Stocks With Momentum Anomaly

Abbott Labs

Becton, Dickinson and Co.

QuidelOrtho Corp

The Department of Health and Human Services (HHS) promises over $22 billion of funding.

Federal, Private Tie-Ups Boost COVID-19 Testing Volume

BJ`s Wholesale Club Holdings Inc

General Motors

Top Ranked Growth Stocks to Buy for January 14th

Quest Diagnostics

Labcorp Holdings Inc

QIAGEN

The resurgence in coronavirus infections is drawing attention back to the diagnostic testing space.

Testing Space in Focus Again Thanks to New Wave of Coronavirus

Hologic (HOLX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Here is Why Growth Investors Should Buy Hologic (HOLX) Now

Investors are optimistic about Hologic's (HOLX) impressive preliminary results for the first quarter of fiscal 2021 and regulatory approvals.

Hologic (HOLX) Hits a New 52-Week High: What's Driving It?

The uptick in Hologic's (HOLX) Diagnostics sales is likely the result of increased demand for COVID-19 testing.

Hologic (HOLX) Rides on Robust Preliminary Q1 Organic Sales

Hologic (HOLX) aims to strengthen its Diagnostics business by foraying into the oncology adjacency space via the acquisition of Biotheranostics.

Hologic (HOLX) to Expand in Oncology With Biotheranostics Buyout

Shares of Hologic Inc. are up 5% in premarket trading Friday after the medical technology company posted preliminary revenue figures ahead of the consensus forecast. The company expects to report revenue of $1.61 billion for its fiscal first quarter that ended Dec. 26, up from $850.5 million a year earlier.

Hologic stock gains after company offers upbeat revenue numbers

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #earnings--Hologic to Announce Financial Results for the First Quarter of Fiscal 2021 on Wednesday, January 27, 2021

Hologic to Announce Financial Results for the First Quarter of Fiscal 2021 on Wednesday, January 27, 2021

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #earnings--Hologic Announces Preliminary Financial Results for First Quarter of Fiscal 2021

Hologic Announces Preliminary Financial Results for First Quarter of Fiscal 2021

In my November 2020 article on Hologic Inc. (HOLX), I opined that the company was likely to pursue acquisitions given the windfall from sales of its Covid-19 diagnostic tests. It didn't take long for the Marlborough, Massachusetts-based medtech to pull the trigger, making two deals—one big, one small—on consecutive days this week.

Covid Testing Bonanza Helps Drive Hologic Acquisitions

The shares of Hologic Inc (NASDAQ:HOLX) are up 2.4% at $77.87 at last check, amid news that the medical technology company will acquire Biotheranostics, a developer of diagnostic, prognostic, and predictive tests supporting cancer patient treatment, for $230 million.

Wheeling and Dealing Hologic Stock Hits Record Highs

Hologic (HOLX) to expand biopsy portfolio as well as enhance patient experience via the SOMATEX buyout.

Hologic (HOLX) Completes SOMATEX Buyout, Expands Portfolio

Medical technology company Hologic Inc. said late Tuesday it has agreed to buy privately held Biotheranostics Inc. for $230 million. Biotheranostics, which generated about $33 million in revenue last year, provides molecular diagnostic tests for breast and metastatic cancers.

Hologic to buy privately held cancer-test maker for $230 million

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #breastcancer--Hologic to Acquire Biotheranostics, Leader in Molecular Tests for Breast and Metastatic Cancers, for Approximately $230 Million

Hologic to Acquire Biotheranostics, Leader in Molecular Tests for Breast and Metastatic Cancers, for Approximately $230 Million

Crocs

Deere & Company

Lennar

Sysco

These top-ranked stocks are likely to beat on bottom line in their next releases.

5 Top-Ranked Stocks Poised to Beat Earnings Estimates

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #biopsy--Hologic to Acquire SOMATEX, Leader in Biopsy Site Markers and Localization Technologies, for $64 Million

Hologic to Acquire SOMATEX, Leader in Biopsy Site Markers and Localization Technologies, for $64 Million

IDEXX Laboratories

Owens & Minor

ResMed

We have selected five MedTech growth stocks with further rooms for improvement in 2021.

5 Soaring MedTech Stocks to Buy for More Growth in 2021

Discover

Honda

Vale S.A.

Winnebago

With other things remaining constant, a stock with higher earnings yield has the potential of providing comparatively greater returns. Check out these five high earnings yield picks for a winning portfolio.

5 High Earnings Yield Stocks to Make You Richer in 2021

Avantor Inc.

HCA Healthcare

Catalent

Guardant Health Inc

As is the case every year, the major Wall Street firms we cover here at 24/7 Wall St.

Analysts' Top Health Care Stocks to Buy Could Be Big 2021 Winners

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #JPMorganconference--Hologic to Webcast Presentation at the 39th Annual J.P. Morgan Healthcare Conference

Hologic to Webcast Presentation at the 39th Annual J.P. Morgan Healthcare Conference

FedEx

Liberty Broadband

Micron Technology

It will be prudent invest in momentum stocks that have surged year to date and sport a top Zacks Rank. These are FDX, HOLX, LEN, LBRDA and MU.

News for Hologic Stock (HOLX)